KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Non-Current Assets (2018 - 2025)

Esperion Therapeutics (ESPR) has disclosed Non-Current Assets for 8 consecutive years, with $3.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Assets fell 43.05% year-over-year to $3.3 million, compared with a TTM value of $16.6 million through Dec 2025, down 38.58%, and an annual FY2025 reading of $3.3 million, down 43.05% over the prior year.
  • Non-Current Assets was $3.3 million for Q4 2025 at Esperion Therapeutics, down from $3.6 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $54.6 million in Q3 2021 and bottomed at $1.2 million in Q1 2023.
  • Average Non-Current Assets over 5 years is $17.0 million, with a median of $5.3 million recorded in 2021.
  • The sharpest move saw Non-Current Assets surged 874.13% in 2022, then tumbled 97.67% in 2023.
  • Year by year, Non-Current Assets stood at $52.6 million in 2021, then plummeted by 97.61% to $1.3 million in 2022, then skyrocketed by 276.67% to $4.7 million in 2023, then grew by 23.08% to $5.8 million in 2024, then crashed by 43.05% to $3.3 million in 2025.
  • Business Quant data shows Non-Current Assets for ESPR at $3.3 million in Q4 2025, $3.6 million in Q3 2025, and $4.5 million in Q2 2025.